Diffusion Pharmaceuticals Inc.

NasdaqCM:DFFN Stock Report

Mkt Cap: US$11.8m

We’ve recently updated our valuation analysis.

Diffusion Pharmaceuticals Valuation

Is DFFN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DFFN?

Other financial metrics that can be useful for relative valuation.

DFFN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does DFFN's PB Ratio compare to its peers?

The above table shows the PB ratio for DFFN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average1.3x
ALRN Aileron Therapeutics
0.6x-10.6%US$13.5m
OPGN OpGen
0.9x25.9%US$12.3m
CLXT Calyxt
1.7x37.5%US$15.1m
BIAF bioAffinity Technologies
1.9xn/aUS$23.4m
DFFN Diffusion Pharmaceuticals
0.5x21.4%US$11.8m

Price-To-Book vs Peers: DFFN is good value based on its Price-To-Book Ratio (0.5x) compared to the peer average (1.3x).


Price to Earnings Ratio vs Industry

How does DFFN's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a14.1%
n/an/an/a

Price-To-Book vs Industry: DFFN is good value based on its Price-To-Book Ratio (0.5x) compared to the US Biotechs industry average (1.8x)


Price to Book Ratio vs Fair Ratio

What is DFFN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DFFN PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate DFFN's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of DFFN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate DFFN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate DFFN's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst DFFN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$5.80
US$24.75
+326.7%
61.6%US$40.00US$9.50n/a2
Jan ’24US$5.06
US$24.75
+389.4%
61.6%US$40.00US$9.50n/a2
Dec ’23US$6.14
US$24.75
+303.1%
61.6%US$40.00US$9.50n/a2
Nov ’23US$4.99
US$24.75
+396.0%
61.6%US$40.00US$9.50n/a2
Oct ’23US$5.35
US$24.75
+362.6%
61.6%US$40.00US$9.50n/a2
Sep ’23US$6.45
US$24.75
+283.7%
61.6%US$40.00US$9.50n/a2
Aug ’23US$6.51
US$40.00
+514.4%
0%US$40.00US$40.00n/a1
Jul ’23US$6.77
US$40.00
+490.8%
0%US$40.00US$40.00n/a1
Jun ’23US$7.75
US$40.00
+416.1%
0%US$40.00US$40.00n/a1
May ’23US$6.18
US$100.00
+1,518.1%
0%US$100.00US$100.00n/a1
Apr ’23US$12.28
US$100.00
+714.7%
0%US$100.00US$100.00n/a1
Mar ’23US$12.50
US$100.00
+700.0%
0%US$100.00US$100.00n/a1
Feb ’23US$14.73
US$100.00
+578.9%
0%US$100.00US$100.00n/a1
Jan ’23US$15.25
US$100.00
+555.7%
0%US$100.00US$100.00US$5.061
Dec ’22US$18.15
US$100.00
+451.0%
0%US$100.00US$100.00US$6.141
Nov ’22US$23.37
US$100.00
+328.0%
0%US$100.00US$100.00US$4.991
Oct ’22US$25.50
US$100.00
+292.2%
0%US$100.00US$100.00US$5.351
Sep ’22US$29.04
US$100.00
+244.4%
0%US$100.00US$100.00US$6.451
Aug ’22US$27.51
US$100.00
+263.5%
0%US$100.00US$100.00US$6.511
Jul ’22US$35.90
US$100.00
+178.6%
0%US$100.00US$100.00US$6.771
Jun ’22US$34.86
US$100.00
+186.9%
0%US$100.00US$100.00US$7.751
May ’22US$37.53
US$100.00
+166.5%
0%US$100.00US$100.00US$6.181
Apr ’22US$46.09
US$100.00
+117.0%
0%US$100.00US$100.00US$12.281
Mar ’22US$55.50
US$100.00
+80.2%
0%US$100.00US$100.00US$12.501
Feb ’22US$54.50
US$100.00
+83.5%
0%US$100.00US$100.00US$14.731
Jan ’22US$39.75
US$100.00
+151.6%
0%US$100.00US$100.00US$15.251

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies